1. Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial 
Tonko Mardešič, Bernadette Mannaerts, Mostafa Abuzeid, Michael Levy, Han Witjes, Bart C.J.M. Fauser 
Reproductive BioMedicine Online 
Volume 28, Issue 4, Pages (April 2014)
DOI: /j.rbmo
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

2. Figure 1
Number of follicles ⩾11mm during stimulation with corifollitropin alfa (A) and recombinant FSH (B) in early and normal responders. Horizontal lines indicate medians, boxes indicate interquartile ranges and whiskers indicate 5th and 95th percentiles. HCG=day of human chorionic gonadotrophin.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

3. Figure 2
Serum FSH (A and B) and LH (C and D) concentrations during stimulation with corifollitropin alfa (A and C) or recombinant FSH (B and D) in early responders and normal responders. Horizontal lines indicate medians, boxes indicate interquartile ranges and whiskers indicate 5th and 95th percentiles. HCG=day of human chorionic gonadotrophin.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions

4. Figure 3
Serum oestradiol (A and B), inhibin B (C and D) and progesterone (E and F) concentrations during stimulation with corifollitropin alfa (A, C, E) or recombinant FSH (B, D, F) in early responders and normal responders. Horizontal lines indicate medians, boxes indicate interquartile ranges and whiskers indicate 5th and 95th percentiles. HCG=day of human chorionic gonadotrophin.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2014 Reproductive Healthcare Ltd. Terms and Conditions